Tadalafil and vardenafil

Nature Reviews Drug Discovery

Volumn 3, Issue 4, 2004, Pages 295-296

  Neumeyer, Katherine ^b   Kirkpatrick, Peter ^a  

^a Nature Reviews Drug Discovery   (United States)

^b Decision Resources Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOMORPHINE; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROSTAGLANDIN E1; SILDENAFIL; TADALAFIL; VARDENAFIL;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG APPROVAL; DRUG CHOICE; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG MARKETING; DRUG MECHANISM; DRUG SELECTIVITY; DRUG STRUCTURE; ERECTILE DYSFUNCTION; HUMAN; NOTE; PENIS PROSTHESIS; PREVALENCE; PRIORITY JOURNAL; PROSTATECTOMY; PSYCHOTHERAPY; SIDE EFFECT;

EID: 16544391738     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1362     Document Type: Note

References (10)

1. Lue, T. F. Erectile dysfunction. N. Engl. J. Med. 342, 1802-1813 (2000).
2. NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence. JAMA 270, 83-90 (1993).
3. Rotella, D. P. Phosphodiesterase 5 inhibitors: current status and potential applications. Nature Rev. Drug Disc. 1, 674-682 (2002).
4. Terrett, N. K. et al. Sildenafil (Viagra), a potent and selective inhibitor of type 5 cGMP phosphodiesterase with utility for the treatment of male erectile dysfunction. Bioorg. Med. Chem. Lett. 6, 1819-1824 (1996).
5. Daugan, A. et al. The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 1:5,6,11,11a-tetrahydro-1H-imidazo[1′,5′:1,6]pyrido[3,4- b]indole-1,3(2H)-dione analogues. J. Med. Chem. 46, 4525-4532 (2003).
6. Daugan, A. et al. The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 2: 2,3,6,7,12,12a-hexahydropyrazino[1′,2′ :1,6]pyrido[3,4-b]indole-1,4-dione analogues. J. Med. Chem. 46, 4533-4542 (2003).
7. Haning, H. et al. Imidazo[5,1-f][1,2,4]triazin-4(3H)-ones, a new class of potent PDE 5 inhibitors. Bioorg. Med. Chem. Lett. 12, 865-868 (2002).
8. FDA Drug Approvals List [online], (cited 10 Feb 2004), (2003).
9. FDA Drug Approvals List [online], (cited 10 Feb 2004), (2003).
10. Rajfer, J. et al. Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. N. Engl. J. Med. 326, 90-94 (1992).